FDA approves 23andMe's hereditary CRC test - 4 insights | PE, reimbursement & more: 5 things to know about GI for ASCs | Ascension restructures leadership as 3 execs depart | Surgery Partners aims for 10%-16% CAGR long term

January 24, 2019

Today's Top Stories

1. Private equity, reimbursement & more: 5 things to know about GI for ASCs

Full story

FDA approves DNA testing company 23andMe's hereditary CRC test - 4 insights Full story

3. Join Katie Couric and former presidents George W. Bush and Bill Clinton + over 300 hospital and health system executive speakers at Becker's Hospital Review 10th Annual Meeting. Register here. | Join Terry Bradshaw and Bobbi Brown + over 170 hospital and health system clinical leaders speaking at Becker's Health IT + Clinical Leadership + Pharmacy Conference. Register here. For exhibiting and sponsorship opportunities, email Jessica Cole at jcole@beckershealthcare.com.

4. Ascension restructures leadership as 3 execs depart Full story

5. Diligent tracking of pack changes can deliver measurable value for supply chain. Register for this upcoming webinar and discover new strategies for increasing supply chain value.

6. Surgery Partners aims for 10%-16% CAGR long term - 5 key points on growth Full story

7. GI leader to know: Dr. Isaac Raijman of CHI Baylor St. Luke's Hospital Full story

8. 5 stages of mobile maturity in healthcare: A framework for clinical mobility assessment and planning. Click here to download the white paper.

9. This GI biopsy firm's sales surged in Q4 - 5 things to know Full story